Genmab A/S
GMABToday
+1.69%
5 Days
-6.01%
1 Month
+46.33%
6 Months
+98.19%
Year to Date
+74.12%
1 Year
+87.12%
Key Figures
• Genmab's Phase 3 LiGeR-HN1 trial met both primary endpoints successfully. • Major research firms issued stock upgrades and target price revisions. • Genmab reported annual revenue of $3.72B and net profit of $963M.
• Genmab's Phase 3 trial for rinatabart sesutecan successfully met primary and secondary endpoints. • Steady DARZALEX royalty revenue and positive epcoritamab results boost institutional investor confidence. • Genmab reports $3.72B annual revenue and an average analyst price target of $45.02.
• Genmab reported positive clinical trial results for rinatabart sesutecan and epcoritamab. • Wall Street analysts increased price targets following the strong pipeline progress. • Institutional investments and favorable technical indicators drove substantial stock momentum.
Genmab A/S's Score
Media Coverage
Analyst Rating
Genmab A/S Technical Analysis
Financial Indicators
Earnings
Genmab A/S Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Orbis Investment Management Ltd. | 2.35% |
| AllianceBernstein L.P. | 1.77% |
| Paradigm BioCapital Advisors LP | 1.15% |
| Arrowstreet Capital, Limited Partnership | 0.81% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor/Hedge Fund | 5.75% |
| Investment Advisor | 3.72% |
| Hedge Fund | 2.33% |
| Research Firm | 0.24% |
Related Instruments
Popular Instruments
